Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Heart Failure VI: Adjunct Therapies

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.

Heart Failure Drugs: Diuretics

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...

Heart Failure V: Medical Management

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...

Heart Failure II: Pathophysiology

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...

Heart Failure IV: Classification and Diagnostic Evaluation

Heart Failure IV: Classification and Diagnostic Evaluation

Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Erratum to Loss of GalNAc-T14 links O-glycosylation defects to alterations in B cell homing in IgA nephropathy.

The Journal of clinical investigation·2026

Same author

A case of early pregnancy pulmonary embolism following mifepristone administration: a call for increased pharmacovigilance and research.

Blood transfusion = Trasfusione del sangue·2026

Same author

Sudden bilateral ocular pain, conjunctival redness and blurred vision with halos at hemodialysis start: an eye of attention for the nephrologist! Lessons for the Clinical Nephrologist.

Journal of nephrology·2026

Same author

DPP-4 inhibitors in current diabetes care: their foundational role in treating to target.

Diabetes research and clinical practice·2026

Same author

Multidrug-Resistant Gram-Negative Urinary Tract Infections (UTIs) Increase the Risk of Rejection, CMV Viremia, and Graft Loss After Kidney Transplantation.

Transplant infectious disease : an official journal of the Transplantation Society·2026

Same author

Acute Gastrointestinal Bleeding: An Update and a Practical Diagnostic Approach.

Diagnostics (Basel, Switzerland)·2026

Search research articles

Related Experiment Video

Updated: May 17, 2026

Bedside Ultrasound for Guiding Fluid Removal in Patients with Pulmonary Edema: The Reverse-FALLS Protocol

Bedside Ultrasound for Guiding Fluid Removal in Patients with Pulmonary Edema: The Reverse-FALLS Protocol

Published on: July 28, 2018

[Ultrafiltration in heart failure].

Riccardo Antoniotti¹, Elio Antonucci, Elena Cremaschi

¹Dipartimento di Clinica Medica, Nefrologia e Scienze della Prevenzione, Università degli Studi di Parma, Parma, Italy.

Giornale Italiano Di Nefrologia : Organo Ufficiale Della Societa Italiana Di Nefrologia

|November 3, 2012

Summary

Ultrafiltration can safely remove fluid overload in heart failure patients. However, it should be reserved for select cases with diuretic resistance, not as a routine treatment.

More Related Videos

Three-Dimensionally Printed Microfluidic Cross-flow System for Ultrafiltration/Nanofiltration Membrane Performance Testing

Three-Dimensionally Printed Microfluidic Cross-flow System for Ultrafiltration/Nanofiltration Membrane Performance Testing

Published on: February 13, 2016

Related Experiment Videos

Last Updated: May 17, 2026

Bedside Ultrasound for Guiding Fluid Removal in Patients with Pulmonary Edema: The Reverse-FALLS Protocol

Bedside Ultrasound for Guiding Fluid Removal in Patients with Pulmonary Edema: The Reverse-FALLS Protocol

Published on: July 28, 2018

Three-Dimensionally Printed Microfluidic Cross-flow System for Ultrafiltration/Nanofiltration Membrane Performance Testing

Three-Dimensionally Printed Microfluidic Cross-flow System for Ultrafiltration/Nanofiltration Membrane Performance Testing

Published on: February 13, 2016

Area of Science:

Cardiology and Nephrology
Fluid Management in Heart Failure

Context:

Fluid overload, manifesting as congestion, is a critical challenge in heart failure management.
Ultrafiltration (UF) techniques, including isolated UF and peritoneal UF, are emerging as options for fluid overload correction.

Purpose:

To review the operational background, safety, efficacy, and cost of various ultrafiltration modalities in heart failure patients.
To evaluate the current evidence for UF in managing fluid overload in heart failure.

Summary:

Isolated UF appears safe and effective for fluid removal in heart failure but lacks evidence for widespread use over diuretics.
Peritoneal UF shows promise but requires larger trials; both methods are best reserved for advanced heart failure with diuretic resistance.

Impact:

Current evidence supports using UF selectively in advanced heart failure with diuretic resistance as part of a comprehensive fluid management strategy.
Further research, particularly large-scale randomized controlled trials, is needed to solidify the role of peritoneal UF.